2025-11-13T12:27:11-05:00 2024-12-31 860839652 ECKELBERG & WIENSHIENK PC 5843 E ORANGE BLOSSOM LANE PHOENIX AZ 850186730 990 2024-01-01 860818253 INTERNATIONAL CANCER ADVOCACY NETWORK INTE 6026180183 27 WEST MORTEN AVENUE PHOENIX AZ 85021 MARCIA K HORN JD PRESIDENT AND CEO 6026180183 2025-11-13 true true DUANE ECKELBERG P00106799 4804231888 2025-11-13 2024 2025-03-06 01:10:19Z ICAN MARCIA K HORN JD 27 WEST MORTEN AVENUE PHOENIX AZ 85021 3081703 false X WWW.ASKICAN.ORG X 1995 AZ ICAN ASSISTS STAGE IV CANCER PATIENTS WITH DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES, INCLUDING PHYSICIAN REFERRALS, AS WELL AS ACCESS TO MOLECULAR PROFILING AND CLINICAL TRIALS. 6 5 1 136 0 1467491 2692996 0 13201 58103 -29376 -29085 1451316 2722014 300000 360000 0 211957 220518 0 16118 515948 650227 1027905 1230745 423411 1491269 3781783 5274894 14196 20722 3767587 5254172 X ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME CANCER, PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE US AND ABROAD WITH CUSTOMIZED INFORMATION SERVICES. ICAN ANNUALLY AWARDS R false false 679792 360000 PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 360,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, DANA-FARBER CANCER INSTITUTE AND CITY OF HOPE. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS,AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2024-2025 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE AND PRACTICE CHANGING JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, THE PD-L1 AMPLIFIEDS, AND THE NRG1 ENERGIZERS. 225917 PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING FOR THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 22 STATES AND COUNTING); SUPPORTING CO-PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL- FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012. 248520 MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS. 1154229 true true false false false false false false false false true false false false false false false false false false false false false false true false false true false true false false false false false false true false true false false false false true false false false true 14 0 1 true false false false false false true true false false false false false false false false X 6 5 false false false false false false false true true false false true true true true true true true true false X X CHAIR BOARD GOVERNANCE COMMITTEE 6026180183 27 WEST MORTEN AVENUE PHOENIX AZ 85021 SHERRY WEINSTEIN CHAIR-TTEES- 30.00 X X 0 0 0 MARCIA K HORN JD PRESIDENT AN 90.00 X X 190000 0 17571 CATHY DALZELL CHAIR ADIVIS 15.00 X X 0 0 0 CHERYL J HINTZEN-GAINES CHAIR-HONORA 3.00 X X 0 0 0 SIDNEY M ROSEN ESQ FOUNDING CHA 10.00 X X 0 0 0 DONNA STONE CHAIR, NATIO 15.00 X X 0 0 0 190000 17571 1 false true false J S HORNPHD 27 W MORTEN AVE PHOENIX AZ 85021 GOVT RELATIONS 167004 1 151392 2541604 311885 2692996 79953 79953 290034 311884 -21850 -21850 -21850 18720 151392 47805 -29085 2722014 -21850 79953 X 360000 360000 190000 180500 3800 5700 17571 16693 351 527 12947 12300 259 388 3050 3050 9075 9075 414980 414980 1663 1663 28837 20715 3784 4338 37434 6947 30487 44486 15269 29217 81510 81510 4099 4099 PROFESSIONAL COUNCILS 11074 1074 7500 2500 BANK CHARGES/FEES 7817 4940 212 2665 BOOKS AND SUBSCRIPTIONS 3074 2745 329 DUES AND SEMINARS 2713 2713 415 105 310 1230745 1131229 83398 16118 676721 1007776 2451238 3613599 305 661505 7986 653519 653519 3781783 5274894 13466 20722 730 14196 20722 X 3767587 5254172 3767587 5254172 3781783 5274894 1491269 -4684 X false false false X 987239 971858 1378104 1467491 2692996 7497688 987239 971858 1378104 1467491 2692996 7497688 7497688 521 912 3327 8481 79953 93194 10010 17160 21980 15860 18720 83730 7674612 18720 0.97690 0.99070 X PART II, LINE 10 GROSS GOLF EVENT PROCEEDS 83,730 RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7986 7986 653519 653519 653519 FISTBUMP FUNDRA 91080 91080 GOLF INVITATION 79032 60312 18720 47805 170112 151392 18720 47805 47805 -29085 true HEYMACH LAB-MD ANDERSON CANCER CNTR UNIV OF TX-1515 HOLCOMBE BLVD HOUSTON TX 77030 746001118 170A 125000 ACTIONABLE MUTATIONS O'CONNOR LAB-CNTR CELLULAR IMMUNO 3400 CIVIC CENTER BLVD BLDG 421 PHILADELPHIA PA 19104 231352685 501C3 50000 IMMUNOTHERAPY RESRCH ECK LAB-DANA-FARBER INSTITUE 450 BROOKLINE AVE BOSTON MA 02215 042263040 501C3 100000 ONCOLOGY RESEARCH JOHN MINNA LAB-U-TX SOUTHWESTERN 6000 HARRY HINES BLVD DALLAS TX 75390 752655008 501C3 50000 ACTIONABLE MUTATIONS CITY OF HOPE CANCER CNTR DUARTE 1500 E DUARTE RD DUARTE CA 91010 953435919 501C3 25000 ONCOLOGY RESEARCH JACKIE BANANA FOUNDATION 416 PARK ST BIRMINGHAM MI 48009 923929257 501C3 10000 CLINICAL TRIALS TRVL 7 SCHEDULE I, PAGE 1, PART I, LINE 2 ICAN HAS AWARDED RESEARCH GRANTS TO THE NAMED LABORATORIES AND INVESTIGATORS. REPRESENTATIVES OF ICAN AWARDEES PROVIDE PERIODIC UPDATES ON THEIR PROGRESS TO ICAN'S CEO AND TO MEMBERS OF THE GRANT COMMITTEE. RESEARCH GRANT FUNDS ARE SOLELY SPENT WITHIN THE UNITED STATES. X X X false false false false false false false false false MARCIA K HORN JD PRESIDENT AND CEO 190000 17571 207571 J S HORN PHD FAMILY MEMBER 167004 INDEPENDNT CONTRACTR false SCHEDULE L, PART V SCH L, PART IV(1)-J.S. HORN, PHD, DIRECTOR, GOVERNMENTAL RELATIONS (STATE, FEDERAL, INTERNATIONAL),FAMILY MEMBER OF BOARD MEMBER X 5 311885 DATE CONTRIBUTED FMV false true false FORM 990 - ORGANIZATION'S MISSION ICAN'S MISSION IS TWO-FOLD: TO OPTIMIZE STAGE IV CANCER PATIENT SURVIVAL AND WORK TO ATTAIN THE HIGHEST POSSIBLE QUALITY OF LIFE. ICAN ASSISTS STAGE IV CANCER PATIENTS WITH 1) DIRECT PATIENT NAVIGATION AND CUSTOMIZED ADVOCACY SERVICES; 2) REFERRALS TO ONCOLOGISTS IN ACADEMIC MEDICAL CENTERS AS WELL AS COMMUNITY PRACTICES; 3) EDUCATING PATIENTS REGARDING THE IMPERATIVE OF MOLECULAR PROFILING; 4) EXPEDITING ACCESS TO MOLECULAR PROFILING; 5) EDUCATING PATIENTS AND THEIR CARE PARTNERS REGARDING CLINICAL TRIALS AND MOLECULAR MATCHING OF THE PATIENT TO CLINICAL TRIALS; AND 6) EXPEDITING PATIENT ACCESS TO COMPASSIONATE USE/EXPANDED ACCESS PROGRAMS. ICAN IS A PAN-HEME CANCER, PAN-SOLID TUMOR, PAN-SARCOMA, AND PAN-RARE CANCER PATIENT ADVOCACY ORGANIZATION AND RESEARCH ADVOCACY ORGANIZATION. ICAN ALSO FOCUSES ON EXPANDING PATIENT ACCESS AND GALVANIZING OUR COLLABORATORS TO ASSIST UNDER-RESOURCED PATIENT COMMUNITIES IN THE US AND ABROAD WITH CUSTOMIZED INFORMATION SERVICES. ICAN ANNUALLY AWARDS RESEARCH GRANTS BASED ON SPECIAL EVENT PROCEEDS AND SPONTANEOUS MEMORIAL AND TRIBUTE DONATIONS SUPPORTING OUR INTERNATIONAL RESEARCH CONSORTIUM'S GOAL TO DEFEAT RARE CANCERS SUCH AS EGFR EXON 20, HER2 EXON 20, MET ALTERATIONS, AND NRG1 FUSIONS. ICAN'S OVERARCHING FOCUS IS OUR DETAIL-ORIENTED PATIENT PROGRAM SERVICES AND RESEARCH ADVOCACY SERVICES WORKING CLOSELY WITH PATIENTS, CARE PARTNERS, THORACIC ONCOLOGISTS, CLINICIANS IN SPECIALTY AREAS, SCIENTISTS, AND INVESTIGATORS WHO SHARE OUR RESEARCH GOALS. SEE ASKICAN.ORG AND UNDER THE ICAN NONPROFIT UMBRELLA: EXON20GROUP.ORG, BIOMARKERCOLLABORATIVE.ORG, METCRUSADERS.ORG,PDL1AMPLIFIEDS.ORG, AND NRG1ENERGIZERS.ORG. FORM 990, PAGE 2, PART III, LINE 4A PATIENT NAVIGATION PROGRAMS, INCLUDING PATIENT PROGRAM SERVICES/RESEARCH ADVOCACY PROGRAMS/CANCER RESEARCH SERVICES OF WHICH 360,000 WAS AWARDED IN GRANTS TO INVESTIGATORS ASSOCIATED WITH OR COLLABORATING WITH ICAN'S INTERNATIONAL RESEARCH CONSORTIUM, INCLUDING THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER, THE UNIVERSITY OF TEXAS SOUTHWESTERN, THE UNIVERSITY OF PENNSYLVANIA, DANA-FARBER CANCER INSTITUTE AND CITY OF HOPE. GRANTS WERE AWARDED FOR PROPOSALS RELATING TO MOLECULAR ALTERATIONS AND RESISTANCE MECHANISMS, DEVELOPMENT OF DRUGS WITH NEW MECHANISMS OF ACTION, DEVELOPMENT OF EARLY DETECTION ASSAYS,AND RESEARCH REGARDING LEPTOMENINGEAL DISEASE (LMD). THE 2024-2025 GRANT CYCLE WAS FUNDED BY ICAN'S SPECIAL EVENTS, INCLUDING THE ANNUAL FISTBUMP FUNDRAISER AND THE ANNUAL APPLIED UNDERWRITING GOLF TOURNAMENT AS WELL AS BY ICAN MEMORIAL AND TRIBUTE PROGRAMS. ICAN'S EXON 20 INTERNATIONAL RESEARCH CONSORTIUM CONSISTS OF TOP THORACIC RESEARCH ONCOLOGISTS AND SCIENTISTS WHO HAVE PRODUCED AN ARRAY OF TRANSFORMATIVE AND PRACTICE CHANGING JOURNAL ARTICLES THAT ARE PROPELLING THE FIELD OF ACTIONABLE MUTATIONS FORWARD. ICAN'S PATIENT SERVICES FOCUS ON HEMATOLOGICAL, SOLID TUMOR, SYNCHRONOUS CANCERS, AND RARE CANCERS. OUR PATIENTS, CARE PARTNERS, AND RESEARCH ADVOCATES REVIEW CLINICAL TRIAL CONCEPTS, PROTOCOLS, AND INFORMED CONSENT FORMS. THE ORGANIZATION'S ONCOLOGY NURSING SERVICES AND ANGEL BUDDIES/MET MENTORS (PEER-TO-PEER PATIENT AND CARE PARTNER ADVISORS) ASSIST PATIENTS AND THEIR FAMILIES WITH SIDE EFFECTS MITIGATION STRATEGIES THROUGHOUT CLINICAL TRIALS AND STANDARD TREATMENT. UNDER THE ICAN NONPROFIT UMBRELLA, ICAN MANAGES THE EXON 20 GROUP (EGFR EXON 20 WARRIORS/HER2 WARRIORS), THE MET CRUSADERS, THE BIOMARKER COLLABORATIVE, THE PD-L1 AMPLIFIEDS, AND THE NRG1 ENERGIZERS. FORM 990, PAGE 2, PART III, LINE 4B PATIENT, CARE PARTNER, AND CLINICIAN EDUCATION/ U.S. AND GLOBAL PATIENT ACCESS PROGRAMS-FOCUSING ON PATIENT ACCESS TO MOLECULAR TESTING AND PRECISION MEDICINE; U.S. AND GLOBAL ACCESS ISSUES RELATED TO UNDER- RESOURCED PATIENT COMMUNITIES; EARLY DETECTION (IMAGING AND MOLECULAR DIAGNOSTICS); ONGOING HEALTH INFORMATION PROJECTS FOR EXON 20 GROUP, MET CRUSADERS, BIOMARKER COLLABORATIVE, AND PAN-TUMOR ICAN PROGRAMS; AND ACCESS ISSUES REGARDING EXPANDED ACCESS/PRE-APPROVAL ACCESS/COMPASSIONATE USE PROGRAMS IN THE U.S. AND ABROAD. ICAN'S PUBLIC POLICY ADVOCACY EFFORTS WERE VIGOROUSLY PURSUED AT THE STATE AND FEDERAL LEVELS, INCLUDING ISSUES SUCH AS THE INFLATION REDUCTION ACT AND FIXING THE SMALL MOLECULE PENALTY; WEIGHING IN ON PRESCRIPTION DRUG AFFORDABILITY BOARDS; SUPPORTING PBM REFORM; SUPPORTING 340B PROGRAM REFORM; ADVOCATING FOR THE PRESERVATION OF THE BAYH-DOLE PROGRAM; SUPPORTING BIOMARKER TESTING BILLS (PASSED IN 22 STATES AND COUNTING); SUPPORTING CO-PAY ACCUMULATOR AND REBATE REFORM BILLS (ACTIVE PARTICIPANT IN THE "ALL COPAYS COUNT COALITION"), AND OPPOSING STATE-LED EFFORTS THAT IMPEDE PATIENT ACCESS TO NOVEL THERAPEUTICS, SUCH AS STEP THERAPY/FAIL- FIRST THERAPY WHERE WE HAVE VIGOROUSLY OPPOSED THOSE ANTI-PATIENT PRACTICES SINCE 2012. FORM 990, PAGE 2, PART III, LINE 4C MOLECULAR PROFILING CONNECTION SERVICES/CLINICAL TRIALS MATCHING SERVICES: 1) ADVISING PATIENTS ON THE IMPORTANCE OF NEXT-GENERATION SEQUENCING AND EDUCATING THEM ABOUT THE ARRAY OF MOLECULAR PROFILING TECHNOLOGIES THAT CAN EITHER BE ACCESSED BY PATIENTS AND/OR RESEARCHERS--DNA, RNA, AND THUS MULTI-OMICS: GENOMICS, PROTEOMICS, TRANSCRIPTOMICS, METABOLOMICS, METHYLATION, IMMUNE CELL STUDIES, AND SO FORTH; 2) REVIEWING MOLECULAR PROFILING REPORTS WITH PATIENTS AND THEIR CARE PARTNERS; 3) CONVENING AD HOC MOLECULAR TUMOR BOARDS WHERE NEEDED, WITH THE INPUT OF MEMBERS OF ICAN'S BIOMARKERS COUNCIL, PHYSICIANS COUNCIL, AND DRUG DEVELOPMENT COUNCIL; 4) EDUCATING PATIENTS ABOUT MOLECULAR TUMOR BOARDS (E.G. TARGET CANCER'S TRACK STUDY, ASCO TAPUR STUDY; ROCHE NAVIFY); AND, 5) CONNECTING PATIENTS TO PRINCIPAL INVESTIGATORS AND STUDY TEAMS ON A PAN-TUMOR/PAN- HEME/PAN-RARE CANCER BASIS IF AN APPROPRIATE CLINICAL TRIAL IS A MOLECULAR MATCH. ICAN AND ITS SUPPORT GROUPS ARE ALSO ENGAGED IN THE AREAS OF DECENTRALIZING TRIALS; "JUST-IN-TIME" TRIALS; AND EXPEDITING THE TRANSFER OF PATIENTS FROM ONE CLINICAL TRIALS SITE (MID-REGIMEN) TO ANOTHER MORE CONVENIENT SITE (U.S. TO U.S. OR EU TO U.S.). ICAN, THE EXON 20 GROUP, AND THE MET CRUSADERS SPECIALIZE IN CLINICAL TRIAL ACCRUAL AND RETENTION ISSUES AS WELL AS CLINICAL TRIALS SITE SELECTION ISSUES. THE BIOMARKER COLLABORATIVE 1) CONNECTS PATIENTS TO BOTH THE APPROPRIATE SPECIFIC BIOMARKER SUPPORT GROUP AND THE RELEVANT GENERAL ORGANIZATIONS THAT COVER THE PATIENT'S SPECIFIC CANCER TYPE; AND 2) EDUCATES PATIENTS ABOUT THEIR DRIVER MUTATION, AMPLIFICATION OR FUSION (IF IDENTIFIED BY THE RELEVANT LABORATORY'S REPORT) AS WELL AS THEIR GENE CO-ALTERATIONS. ICAN AND ITS SUPPORT ORGANIZATIONS EACH STRESS THE IMPORTANCE OF MULTI-STAKEHOLDER COLLABORATIONS WITH RESEARCH ADVOCATES, PATIENT ADVOCATES, COMMUNITY ADVOCATES, CLINICIANS, AND SCIENTISTS. FORM 990, PAGE 6, PART VI, LINE 11B A COPY OF FORM 990 IS PROVIDED TO BOARD MEMBERS FOR THEIR REVIEW BEFORE THE FORM 990 IS FILED. THE CHAIRMAN OF THE BOARD OF TRUSTEES AND THE CHAIRS OF THE GOVERNANCE AND COMPENSATION COMMITTEES REVIEW, WITH ICAN'S CEO, COMMENTS REGARDING DRAFTS OF THE FORM 990. INPUT IS OBTAINED FROM MEMBERS OF ICAN'S INTERNAL AUDIT COMMITTEE AND SPECIAL EVENTS COMMITTEES. AT THE DIRECTION AND APPROVAL OF THE FULL BOARD, A SUBGROUP OF THE ORGANIZATION'S EXECUTIVE OFFICERS THEN COMPLETES ITS FINAL REVIEW, AND THE FORM 990 IS FILED. FORM 990, PAGE 6, PART VI, LINE 12C BOARD MEMBERS ANNUALLY DISCLOSE IN WRITING ALL POTENTIAL OR ACTUAL CONFLICTS OF INTEREST TO THE BOARD GOVERNANCE COMMITTEE. FORM 990, PAGE 6, PART VI, LINE 15A SINCE 2003, THE ORGANIZATION HAS ANNUALLY REVIEWED THE CEO'S COMPENSATION, WITH AN ANALYSIS THAT INCLUDES COMPARISONS TO OTHER CANCER ORGANIZATION CHIEF EXECUTIVE OFFICERS' COMPENSATION AS WELL AS OTHER HEALTH CARE NONPROFIT ORGANIZATION CHIEF EXECUTIVE OFFICERS' SALARIES. SEVERAL YEARS AGO, THE ORGANIZATION BENEFITED FROM AN EXTERNAL ORGANIZATION'S ANALYSIS THAT IS DEVOTED ENTIRELY TO FOR-PROFIT AND NONPROFIT EXECUTIVES' COMPENSATION. THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 15B THE PROCESS AT ICAN INVOLVES THE COMPENSATION COMMITTEE CHAIRMAN'S ANNUAL REVIEW OF THE CEO AND KEY STAFF'S COMPENSATION, ON BEHALF OF THE BOARD OF TRUSTEES, BASED ON INTERNAL AND EXTERNAL INPUTS AND REVIEWS AND THE COMPENSATION COMMITTEE'S RECOMMENDATION TO THE BOARD OF ANY SALARY INCREASE OR EMPLOYEE BENEFITS SUCH AS HEALTH INSURANCE AND OTHER INSURANCE. FORM 990, PAGE 6, PART VI, LINE 19 THE ORGANIZATION'S WEBSITE HAS AN EXTENSIVE BOARD GOVERNANCE SECTION. THE ORGANIZATION'S FORM 990 AS WELL AS ALL BOARD GOVERNANCE DOCUMENTS, INCLUDING CONFLICT OF INTEREST POLICY, WHISTLEBLOWER POLICY, AND DOCUMENTS RETENTION POLICY, ARE AVAILABLE ON ICAN'S WEBSITE (COMPENDIUM OF BOARD POLICIES) AND AT AVAILABLE AT GUIDESTAR/CANDID AS WELL AS CHARITY NAVIGATOR. FORM 990, PART IX, LINE 11G PATIENT SERVICES 132,900 0 0 PATIENT ACCESS 276,004 0 0 OUTSIDE SERVICES 6,076 0 0 TOTAL 414,980 0 0 BIOMARKER COLLABORATIVE INC 27 W MORTEN AVE PHOENIX AZ 85021 883107993 SUPPORT WI 501C3 10 INTERNATL CANCER ADVOCACY NETWORK false MET CRUSADERS INC 4524 BLUE MOUNDS TRAIL BLACK EARTH WI 53515 871238935 SUPPORT WI 503C3 7 INTERNATL CANCER ADVOCACY NETWORK false false false false false false false false false false false false false false false false false false false false